

List of active clinical trials for thymic epithelial tumors (TETs) as of September 29, 2023

Treatment	Study Title	Disease setting	Phase	Country	NCT	Study contact
<b>Neoadjuvant treatment</b>						
<b>Chemotherapy/toripalimab</b> (anti-PD-1)	Clinical study of neoadjuvant PD-1 antibody (Toripalimab) plus chemotherapy for locally advanced thymic epithelial tumor	Stage III-IVA T and TC	2	China	NCT04667793	<a href="mailto:zhangpeng1121@tongji.edu.cn">zhangpeng1121@tongji.edu.cn</a>
<b>Cisplatin/docetaxel/pembrolizumab</b> (anti-PD-1)	neoadjuvant_thymic Epithelial Tumor	Stage III-IVA T and TC	2	South Korea	NCT03858582	<a href="mailto:keunchil.park@samsung.com">keunchil.park@samsung.com</a>
<b>Radiation/envolizumab</b> (subcutaneous PD-L1)	Neoadjuvant Treatment For Locally Advanced Thymic Cancer	Stage III-IVA TC	2	China	NCT06019468	<a href="mailto:yujm96@163.com">yujm96@163.com</a> <a href="mailto:zdp1992@163.com">zdp1992@163.com</a>
<b>First line systemic treatment for advanced disease</b>						
<b>Carboplatin/paclitaxel +/- ramucirumab</b> (VEGFR2 inhibitor)	Carboplatin and paclitaxel with or without ramucirumab in treating patients with locally advanced, recurrent, or metastatic thymic cancer that cannot be removed by surgery.	Treatment naïve advanced TC	2	USA	NCT03694002	<a href="mailto:astsao@mdanderson.org">astsao@mdanderson.org</a>
<b>Carboplatin/Taxane/pembrolizumab</b> (anti-PD-1)	Single-arm study to carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab as the first line therapy in treating patients with locally advanced or metastatic invasive thymoma and thymic carcinoma	Advanced T and TC	4	China	NCT04554524	<a href="mailto:Zhou.yongan@163.com">Zhou.yongan@163.com</a>
<b>Carboplatin/paclitaxel/lenvatinib/pembrolizumab</b> (multitargeted tyrosine kinase inhibitor/anti-PD-1)	First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)	Advanced TC	2	Japan	NCT05832827	<a href="mailto:ncch2109_jimukyoku@is-pc.or.jp">ncch2109_jimukyoku@is- pc.or.jp</a>
<b>Second line and beyond systemic treatment for advanced disease</b>						
<b>Nivolumab +/- ipilimumab</b> (anti-PD-1/anti-CTLA4)	Nivolumab in patients with type B3 thymoma and thymic Carcinoma (NIVOTHYM)	Type B3 T and TC	2	Belgium, France, Netherlands, Spain, Switzerland, UK	NCT03134118	<a href="mailto:1525@eortc.org">1525@eortc.org</a>
<b>Nivolumab/vorolanib</b> (anti-PD-1/multi-kinase VEGF/ PDGFR inhibitor)	Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors	TC among other thoracic cancers	1/2	USA	NCT03583086	NA
<b>Avelumab</b> (anti-PD-L1)	A pilot study to investigate the safety and clinical activity of avelumab (MSB0010718C) in thymoma and thymic carcinoma after progression on platinum-based chemotherapy.	Advanced T and TC	2	USA	NCT03076554	<a href="mailto:shannon.swift@nih.gov">shannon.swift@nih.gov</a> <a href="mailto:rajana@mail.nih.gov">rajana@mail.nih.gov</a>
<b>Bintrafusp Alfa</b> (bifunctional fusion protein targeting TGF-β and PD-L1)	Bintrafusp Alfa (M7824) in subjects with thymoma and thymic carcinoma	Advanced T and TC	2	USA	NCT04417660	<a href="mailto:shannon.swift@nih.gov">shannon.swift@nih.gov</a> <a href="mailto:rajana@mail.nih.gov">rajana@mail.nih.gov</a>
<b>Sunitinib</b> (multi-targeted receptor tyrosine kinase)	Trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines (Style Trial)	Type B3 T and TC	2	Italy	NCT03449173	<a href="mailto:marina.garassino@istitutotumor&lt;br/&gt;i.mi.it">marina.garassino@istitutotumor i.mi.it</a> <a href="mailto:rosaria.gallucci@istitutotumor.&lt;br/&gt;mi.it">rosaria.gallucci@istitutotumor. mi.it</a>

<b>PT-112</b> (pyrophosphate-platinum conjugate)	PT-112 in subjects with thymoma and thymic carcinoma	Advanced T and TC	2	USA	NCT05104736	<a href="mailto:shannon.swift@nih.gov">shannon.swift@nih.gov</a> <a href="mailto:rajana@mail.nih.gov">rajana@mail.nih.gov</a>
<b>KC1036</b> (AXL/ FLT3/VEGFR2 inhibitor)	A study of KC1036 in patients with advanced thymic tumors	Advanced T and TC	2	China	NCT05683886	<a href="mailto:Wangys75@gmail.com">Wangys75@gmail.com</a>
<b>Pembrolizumab</b> (anti-PD-1)	Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer	Advanced T and TC	1	USA	NCT03295227	<a href="mailto:astsao@mdanderson.org">astsao@mdanderson.org</a>
<b>Chemotherapy plus cetuximab</b> (Anti-EGFR antibody)	Chemotherapy plus cetuximab followed by surgical resection in patients with locally advanced or recurrent thymoma or thymic carcinoma.	Stage II-IVA thymoma or thymic carcinoma	2	USA	NCT01025089	NA
<b>Pembrolizumab/lenvatinib</b> (anti-PD-1/multitargeted tyrosine kinase inhibitor)	Combination of pembrolizumab and lenvatinib, in pre-treated thymic carcinoma patients (PECATI)	Type B3 T and TC	2	France, Italy, Spain	NCT04710628	<a href="mailto:neus.crespo@medsir.org">neus.crespo@medsir.org</a> <a href="mailto:alicia.garcia@medsir.org">alicia.garcia@medsir.org</a>
<b>177Lu-DOTA-TATE/Olaparib</b> (Radiopharmaceutical for PRRT/PARP inhibitor)	177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours (LuPARP)	T among other tumors	1	Sweden	NCT04375267	<a href="mailto:andreas.hallqvist@vgregion.se">andreas.hallqvist@vgregion.se</a> <a href="mailto:annika.baan@vgregion.se">annika.baan@vgregion.se</a>
<b>KN046</b> (PD-L1/CTLA-4 bispecific antibody)	KN046 (a humanized PD-L1/CTLA4 bispecific single domain Fc fusion protein antibody) in subjects with thymic carcinoma.	Advanced TC	2	China	NCT04469725	<a href="mailto:chestgcp@126.com">chestgcp@126.com</a>
<b>Atezolizumab</b> (Anti-PD-L1)	A study to investigate the efficacy and safety of atezolizumab in previously-treated patients with advanced thymic carcinoma.	Advanced TC	2	China	NCT04321330	NA
<b>Pembrolizumab/sunitinib</b> (Anti-PD-1/ multitargeted tyrosine kinase inhibitor)	Pembrolizumab and sunitinib malate in treating participants with refractory metastatic or unresectable thymic cancer	Advanced TC	2	USA	NCT03463460	<a href="mailto:OSUCCCclinicaltrials@osumc.edu">OSUCCCclinicaltrials@osumc.edu</a> <a href="mailto:Carly.Pilcher@osumc.edu">Carly.Pilcher@osumc.edu</a>
<b>YY-20394</b> (oral phosphatidylinositol 3-kinase delta [PI3Kδ] inhibitor)	A phase 2 clinical study of YY-20394 in patients with relapsed/refractory thymic cancer.	Advanced T and TC	2	NA	NCT04975061	NA
<b>VMD-928</b> (TrkA inhibitor)	Selective TrkA inhibitor VMD-928 to treat TrkA overexpression driven solid tumors or lymphoma.	Advanced T and TC among other tumors	1	USA	NCT03556228	<a href="mailto:OM@VMOncology.com">OM@VMOncology.com</a> <a href="mailto:dadenaik@TD2inc.com">dadenaik@TD2inc.com</a>
<b>KFA115 +/- tislelizumab</b> (undisclosed mechanism/anti-PD-1)	A study of safety and efficacy of KFA115 alone and KFA115 in combination with Tislelizumab in patients with select advanced cancers.	Advanced TC among other tumors	1	USA, Canada, Singapore, Hong Kong Taiwan	NCT05544929	<a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>
<b>SO-C101 +/- pembrolizumab</b> (IL15/IL-15Rα sushi + domain fusion protein / anti-PD-1)	Study of SO-C101 and SO-C101 in combination with pembro in adult patients with advanced/metastatic solid tumors.	Advanced TC among other tumors	1	USA, Czechia, France, Spain	NCT04234113	<a href="mailto:Kapsa@sotio.com">Kapsa@sotio.com</a>
<b>Hyperthermic intrathoracic chemotherapy (HITOC)</b>	Intrathoracic chemotherapy for TETs with pleural spread or recurrence (CHOICE)	T and TC with pleural spread or recurrence	NA	China	NCT05446935	<a href="mailto:ding.jiayong@zs-hospital.sh.cn">ding.jiayong@zs-hospital.sh.cn</a>

<b>Radiotherapy</b>						
<b>Intensity-Modulated Pleural Radiation Therapy (IMPRINT)</b>	A study of intensity-modulated pleural radiation therapy (IMPRINT) in people with thymic cancer that has spread to the lining of the lungs and chest.	T and TC with pleural involvement	2	USA	NCT05354570	<a href="mailto:shephera@mskcc.org">shephera@mskcc.org</a>
<b>Chemoradiotherapy and thymosin <math>\alpha</math>1</b>	Hypofractionated chemoradiotherapy and thymosin $\alpha$ 1 in unresectable or recurrent thymic epithelial tumor	Unresectable or recurrent T and TC	2	China	NCT03663764	NA
<b>Chemoradiation</b>	A randomized phase III study of adjuvant radiotherapy versus adjuvant radiochemotherapy in patients with incomplete resection thymoma or thymic carcinoma.	Incompletely resected (R1 or R2) T and TC	3	China	NCT02633514	<a href="mailto:wukailiang@aliyun.com">wukailiang@aliyun.com</a> <a href="mailto:wenxingfan@126.com">wenxingfan@126.com</a>
<b>Adjuvant RT</b>	Randomized, multicenter, phase III trial to assess conformal post-operative radiotherapy vs. surveillance after complete resection of stage II/III thymoma (RADIO-RYTHMIC)	Stage II/III T	3	France	NCT04731610	<a href="mailto:gilles.nyassemessene@curie.fr">gilles.nyassemessene@curie.fr</a>
<b>Adjuvant RT</b>	An open-label, multi-center, randomized phase III study of adjuvant radiotherapy for stage II/III thymoma after complete resection.	Stage II/III T	3	China	NCT02633553	<a href="mailto:wukailiang@aliyun.com">wukailiang@aliyun.com</a> <a href="mailto:wenxingfan@126.com">wenxingfan@126.com</a>
<b>RT plus rhGM-CSF</b>	Abscopal effect of radiotherapy in combination with rhGM-CSF for advanced thymic epithelial tumours	Stage IV T and TC	2	China	NCT05407649	<a href="mailto:fanming@fudan.edu.cn">fanming@fudan.edu.cn</a>
<b>Proton radiotherapy</b>	Study on proton radiotherapy of thymic malignancies (PROTHYM)	T and TC in the post-operative setting or in inoperable patients with localized disease	NA	Sweden	NCT04822077	<a href="mailto:jan.nyman@oncology.gu.se">jan.nyman@oncology.gu.se</a> <a href="mailto:andreas.hallqvist@vgregion.se">andreas.hallqvist@vgregion.se</a>

NA=Not applicable, T= Thymoma, TC=Thymic carcinoma